E R阳性乳腺癌中FGFR1蛋白的表达与ER及预后的关系

doi:10.19401/j.cnki.1007-3639.2019.05.004

中国癌症杂志 ›› 2019, Vol. 29 ›› Issue (5): 345-351.doi: 10.19401/j.cnki.1007-3639.2019.05.004

E R阳性乳腺癌中FGFR1蛋白的表达与ER及预后的关系

王宇航¹，宋全福²，吴俊强¹，南丁阿比雅斯³，阿勒哈³，庞　达¹，姜永冬¹

1. 哈尔滨医科大学附属肿瘤医院乳腺外科，黑龙江哈尔滨 150081 ；
2. 哈尔滨医科大学附属肿瘤医院病理科，黑龙江哈尔滨 150081 ；
3. 阿勒泰地区人民医院肿瘤科，新疆维吾尔族自治区阿勒泰 836000

出版日期:2019-05-30 发布日期:2019-06-03
通信作者: 姜永冬 E-mail: jiangyongdonghmu@126.com
基金资助:
国家自然科学基金（81202075）。

FGFR1 protein level is associated with ER expression and prognosis in ER-positive breast cancer

WANG Yuhang¹, SONG Quanfu², WU Junqiang¹, Nading Abiyasi³, A Leha³, PANG Da¹, JIANG Yongdong¹

1. Department of Breast Cancer Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China; 2. Department of Pathology, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China; 3. Department of Oncology, Altay Region People’s Hospital, Altay 836000, Xinjiang Uygur Autonomous Region, China

Published:2019-05-30 Online:2019-06-03
Contact: JIANG Yongdong E-mail: jiangyongdonghmu@126.com

摘要/Abstract

摘要： 背景与目的：乳腺癌是严重危害女性健康的常见恶性肿瘤之一，内分泌治疗是乳腺癌综合治疗中的重要措施之一。约30%激素敏感型乳腺癌患者并不能从内分泌治疗中获益。成纤维细胞生长因子受体1（fibroblast growth factor receptors 1，FGFR1）的表达与雌激素受体（estrogen receptor，ER）阳性乳腺癌患者内分泌治疗耐药可能有关。该研究旨在探讨ER阳性乳腺癌中FGFR1蛋白的表达水平对乳腺癌临床病理学特征及预后的影响。方法：选取哈尔滨医科大学附属肿瘤医院2008年9月-2011年12月收治的184例ER阳性乳腺癌患者，通过免疫组织化学方法检测FGFR1蛋白的表达；采用χ²检验评估FGFR1蛋白水平与乳腺癌临床病理学特征的关系；采用Spearman相关分析评估变量间是否存在相关性；运用COX回归及Kaplan-Meier法分析FGFR1表达水平对乳腺癌预后的影响。结果：在ER阳性乳腺癌中，FGFR1高表达的患者更易发生区域淋巴结转移（P=0.012，r=0.186），且FGFR1的表达水平与ER的表达水平之间存在显著的负相关关系（P=0.011，r=-0.221）。COX单因素分析显示，TNM分期、区域淋巴结转移情况、Ki-67阳性率及FGFR1表达情况与ER阳性乳腺癌预后有关；进一步进行多因素分析发现，淋巴结转移情况（OR=1.744，95%CI：1.002~3.034，P=0.049）和Ki-67阳性率（OR=1.882，95%CI：1.015~3.491，P=0.045）是ER阳性乳腺癌的独立风险因素。Kaplan-Meier生存分析提示，FGFR1高表达患者预后不良（P=0.036）。结论：在ER阳性乳腺癌中，FGFR1蛋白水平与患者ER的表达水平呈显著负相关，且FGFR1高表达提示患者预后不良。

关键词: 乳腺癌, 成纤维细胞生长因子受体1, 雌激素受体阳性, 免疫组织化学, 预后

Abstract: Background and purpose: Breast cancer is one of the most common malignancies in women. Endocrine therapy is one of the most important therapeutics in breast cancer systemic therapy. However, about 30% of hormone-sensitive breast cancer patients do not benefit from endocrine therapy. The expression of fibroblast growth factor receptor 1 (FGFR1) may be involved in endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer patients. FGFR1 is widely recognized for playing key roles in mammary carcinogenesis and further affecting the prognosis and therapeutic response of breast cancer. The aim of this study was to investigate the effect of FGFR1 protein expression on the clinicopathological features and prognosis of ERpositive breast cancer. Methods: One hundred and eighty-four ER-positive breast cancer cases treated in Harbin Medical University Cancer Hospital from September 2008 to December 2011 were studied, and their FGFR1 protein expressions were measured by the immunohistochemistry method. Pearson’s chi-square test was utilized to analyze the association between FGFR1 expression and disease characteristics. COX regression and Kaplan-Meier analyses were performed to evaluate the effect of FGFR1 on the prognosis of ER-positive breast cancer. Results: The results showed that patients with higher FGFR1 expression were more likely to have lymph node metastasis (P=0.012, r=0.186), and their ER levels were negatively associated with FGFR1 expression (P=0.011, r=-0.221). In univariate COX regression analyses, TNM stage, regional lymph node metastasis status, Ki-67 positive rate and FGFR1 expression were correlated with the prognosis of ER-positive breast cancer. It was found by multiple factors analysis of data that lymph node metastasis status (OR=1.744, 95%CI: 1.002-3.034, P=0.049) and Ki-67 positive rate (OR=1.882, 95%CI: 1.015-3.491, P=0.045) were independent prognostic factors for ER-positive breast cancer. Kaplan-Meier analysis showed that high indicate FGFR1 expression was correlated with decreased overall survival (P=0.036). Conclusion: There was a significant negative correlation between FGFR1 expression and ER level in ER-positive breast cancer, and high FGFR1 protein level was associated with a poor prognosis.

Key words: Breast cancer, Fibroblast growth factor receptor 1, Estrogen receptor-positive, Immunohistochemistry, Prognosis

王宇航，宋全福，吴俊强，南丁阿比雅斯，阿勒哈，庞　达，姜永冬. E R阳性乳腺癌中FGFR1蛋白的表达与ER及预后的关系[J]. 中国癌症杂志, 2019, 29(5): 345-351.

WANG Yuhang, SONG Quanfu, WU Junqiang, Nading Abiyasi, A Leha, PANG Da, JIANG Yongdong. FGFR1 protein level is associated with ER expression and prognosis in ER-positive breast cancer[J]. China Oncology, 2019, 29(5): 345-351.

[1]	林艺, 王策, 康勋, 康庄, 陈峰, 江波, 李文斌. 胶质母细胞瘤复发相关基因的筛选、表达和临床预后分析[J]. 中国癌症杂志, 2022, 32(1): 13-23.
[2]	章箎, 陈佳慧, 林瑾仪, 王妍, 张斯加, 朱玮, 程蕾蕾. 一种新型《乳腺癌治疗相关心血管毒性临床评分表》的价值分析[J]. 中国癌症杂志, 2022, 32(1): 54-60.
[3]	金奕滋, 林明曦, 张剑. DNA损伤应答缺陷作为乳腺癌治疗靶点的研究进展[J]. 中国癌症杂志, 2022, 32(1): 61-67.
[4]	《中国乳腺癌新辅助治疗专家共识（2022年版）》专家组. 中国乳腺癌新辅助治疗专家共识（2022年版）[J]. 中国癌症杂志, 2022, 32(1): 80-89.
[5]	张小艳, 李清祥, 刘　勇, 李　航, 仇丽娟, 封欣然, 谭立明 . HMGB1与乳腺癌患者临床病理学特征及免疫指标的相关性研究[J]. 中国癌症杂志, 2021, 31(9): 783-788.
[6]	徐　然, 王馨悦, 冯麟媛, 韩安娜, 王艺璇, 杨万山, 刘　超 . 神经胶质瘤中NCAPD2的表达水平及生物学意义[J]. 中国癌症杂志, 2021, 31(9): 789-798.
[7]	曹爱玲, 曹　喆, 周　剑. 多西他赛联合胸腺肽α1对大鼠乳腺癌免疫微环境中Treg数量的影响及其机制研究[J]. 中国癌症杂志, 2021, 31(9): 799-806.
[8]	姚　嘉, 李冠乔, 杨时平, 苏慧銮 . Hsa-miR-98-5p/DKK3信号轴对乳腺癌细胞生物学行为的影响[J]. 中国癌症杂志, 2021, 31(9): 807-816.
[9]	马祎菲, 梁新军, 魏少忠 . 炎症与免疫指标在可切除性结直肠癌中的预后价值[J]. 中国癌症杂志, 2021, 31(9): 845-851.
[10]	丛斌斌, 王永胜. 激素受体阳性早期乳腺癌治疗现状与挑战[J]. 中国癌症杂志, 2021, 31(8): 689-696.
[11]	雷雅洁, 高　毅, 王治洁, 程　玺, 杨雨菲, 周宏宇, 陈丽华, 陈伊新, 李浩然, 李子庭, 吴小华 . 早期卵巢癌（Ⅰ C ~ⅡA）患者腹主动脉旁淋巴结清扫术对预后影响的临床分析[J]. 中国癌症杂志, 2021, 31(8): 740-745.
[12]	朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[13]	高鹤丽, 徐　近, 虞先濬. 分化好的胃肠胰神经内分泌瘤G3的诊治新进展[J]. 中国癌症杂志, 2021, 31(7): 567-573.
[14]	丁高峰, 郭雷鸣, 陆寓非. 乳腺癌患者HER2和BRCA1表达与放疗敏感性的关系研究[J]. 中国癌症杂志, 2021, 31(7): 589-595.
[15]	金优萍, 李录英, 周　平. 长链非编码RNA STMN1P2在乳腺癌中的作用及机制研究[J]. 中国癌症杂志, 2021, 31(7): 596-604.

E R阳性乳腺癌中FGFR1蛋白的表达与ER及预后的关系

FGFR1 protein level is associated with ER expression and prognosis in ER-positive breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价